Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials

Adeela Mushtaq, Ahmad Iftikhar, Hamza Hassan, Midhat Lakhani, F. N.U. Sagar, Ahmad Kamal, Umar Zahid, Zeeshan Ali, Faryal Razzaq, Muhammad Abu Zar, Syeda Fatima Hassan, Ahmad Safdar, Sreejata Raychaudhuri, Faiz Anwer

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

We performed a meta-analysis to evaluate the efficacy outcomes of different pomalidomide (Pom) regimens in relapsed/refractory multiple myeloma (RRMM). Three-drug Pom regimens yielded double the response rates compared to Pom + low-dose dexamethasone (LoDex), and notably better outcomes than bortezomib + Pom + LoDex and carfilzomib + Pom + LoDex. Ongoing trials of Pom with various monoclonal antibodies will provide further insight into the role of pomalidomide for RRMM.

Original languageEnglish (US)
Pages (from-to)447-461
Number of pages15
JournalClinical Lymphoma, Myeloma and Leukemia
Volume19
Issue number7
DOIs
StatePublished - Jul 2019

Keywords

  • Adverse event
  • Immunomodulator
  • Outcome
  • Overall response
  • Pom-dex

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials'. Together they form a unique fingerprint.

  • Cite this

    Mushtaq, A., Iftikhar, A., Hassan, H., Lakhani, M., Sagar, F. N. U., Kamal, A., Zahid, U., Ali, Z., Razzaq, F., Zar, M. A., Hassan, S. F., Safdar, A., Raychaudhuri, S., & Anwer, F. (2019). Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials. Clinical Lymphoma, Myeloma and Leukemia, 19(7), 447-461. https://doi.org/10.1016/j.clml.2019.04.003